Ibrutinib - Janssen/Pharmacyclics
At a glance
- Drug Originator Celera Genomics Group
- Drug Licenced by Janssen; Janssen Biotech
- Drug Class 2 ring heterocyclic compounds; Antiallergics; Antineoplastics; Antirheumatics; Phenyl ethers; Piperidines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors
- USA Patent Applicants PHARMACYCLICS LLC
- USA Patents 95
- NDAs 3
- International Patents 406
- Patent Applications 3,121
Table of Contents
Disclaimer